SeniorJournal.com - Daily News for Senior Citizens

  FRONT PAGE Aging • Health • Alzheimer's - Mental • Nutrition • Medicare & Medicaid Politics  • Fitness  • Social Security • Alerts • Sex Health • Features • Retirement  Elder Care  >Search  >Senior Links

[NavBar.htm]

Senior Journal: Today's News and Information for Senior Citizens & Baby Boomers

More Senior Citizen News and Information Than Any Other Source - SeniorJournal.com

• Go to more on Health & Medicine or More Senior News from SeniorJournal.com on the Front Page

   
Follow on  and 

E-mail this page to a friend!

Health & Medicine for Senior Citizens

Jakafi First Drug Approved by FDA for Bone Marrow Disease Myelofibrosis

Increasing trend in oncology where detailed scientific understanding of mechanisms of a disease allows a drug to be directed toward specific molecular pathways

Nov. 16, 2011 - The U.S. Food and Drug Administration today approved Jakafi (ruxolitinib) as the first drug approved to specifically treat patients with the bone marrow disease myelofibrosis, which normally strikes people age 50 or older.

Myelofibrosis is a disease in which the bone marrow is replaced by scar tissue resulting in blood cells being made in organs such as the liver and the spleen. This disease is marked by an enlarged spleen, anemia, decreased white blood cells and platelets, and myelofibrosis-related symptoms.

 

Related Archive Stories

 
 

New Drug, Evacetrapib, Increases Good Cholesterol, Decreases Bad – Alone or With Statin

The combination of a statin and evacetrapib resulted in greater reductions in LDL but no greater increase in HDL - Nov. 15, 2011

‘Death Is Always Cheaper’ – Capsules: The KHN Blog

Sapien artificial heart valve approved by FDA for use in old, frail patients to gain another year - Nov. 14, 2011


 
 

Read the latest news
> Health & Medicine
>
Today's Headlines

 

Symptoms include fatigue, abdominal discomfort, pain under the ribs, feeling full (satiety), muscle and bone pain, itching, and night sweats.

About Myelofibrosis

Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by scar (fibrous) tissue.

Causes

Bone marrow is the soft, fatty tissue inside your bones. Stem cells are immature cells in the bone marrow that give rise to all of your blood cells. Your blood is made of:

   ● Red blood cells (which carry oxygen to your tissues)

   ● White blood cells (which fight infection)

   ● Platelets (which help your blood clot)

Scarring of the bone marrow means the marrow is not able to make enough blood cells. Anemia, bleeding problems, and a higher risk of infections may occur.

As a result, the liver and spleen try to make some of these blood cells. This causes these organs to swell, which is called extramedullary hematopoiesis.

The cause of myelofibrosis is unknown. There are no known risk factors. The disorder usually develops slowly in people over age 50.

Diseases such as leukemia and lymphoma may also cause bone marrow scarring. This is called secondary myelofibrosis.

Symptoms

   ● Abdominal fullness related to an enlarged spleen

   ● Bone pain

   ● Bruising

   ● Easy bleeding

   ● Fatigue

   ● Increased likelihood of getting an infection

   ● Pallor

   ● Shortness of breath with exercise

>> More from MedlinePLUS

Jakafi, a pill taken two times a day, inhibits enzymes called JAK 1 and 2 (Janus Associated Kinase) that are involved in regulating blood and immunological functioning. Myelofibrosis is associated with the deregulation of JAK 1 and 2.

“Jakafi represents another example of an increasing trend in oncology where a detailed scientific understanding of the mechanisms of a disease allows a drug to be directed toward specific molecular pathways,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

“The clinical trials leading to this approval focused on problems that patients with myelofibrosis commonly encounter, including enlarged spleens and pain.”

The safety and effectiveness of Jakafi was evaluated in two clinical trials with 528 patients. Patients in both trials were resistant or refractory to available myelofibrosis therapy or ineligible for allogeneic bone marrow transplantation (procedure where a person receives blood-forming stem cells from a genetically similar, but not necessarily identical, donor).

All patients had enlarged spleens (splenomegaly) and were in need of treatment as a result of disease-related symptoms.

Patients in the studies were selected to receive treatment with either Jakafi, placebo (sugar pill) or the best available therapy (hydroxyurea, a chemotherapy agent, or glucocorticoids).

A greater percentage of patients receiving Jakafi experienced more than a 35 percent reduction in spleen size when compared to patients receiving placebo or best available therapy.

Similarly, a greater proportion of patients receiving Jakafi saw more than a 50 percent reduction in their myelofibrosis-related symptoms, including abdominal discomfort, night sweats, itching and bone or muscle pain, than was the case in patients receiving placebo.

The most serious side effects seen in patients treated with Jakafi include low blood platelet levels (thrombocytopenia), anemia, fatigue, diarrhea, shortness of breath (dyspnea), headache, dizziness, and nausea.

Jakafi was reviewed under the FDA’s priority review program, an expedited six-month review of drugs that may offer significant advances in treatment over available therapy or that provide a treatment when no adequate therapy exists.

The treatment is being approved ahead of the drug’s Dec. 3, 2011 review goal date under the Prescription Drug User Fee Act and has been designated as an orphan drug, which identifies the disease as affecting fewer than 200,000 people in the U.S.

Jakafi is manufactured by Incyte Corp. of Wilmington, Del.

For more information:

FDA: Office of Hematology and Oncology Products

FDA: Approved Drugs: Questions and Answers2

NCI: Primary Myelofibrosis3

 

> Medical Malpractice,

> Nursing Home Abuse,

> Personal Injury

Our Experienced Lawyers Can Help

Beth Janicek, Board Certified Personal Injury Attorney"We win because we care, we prepare and we have no fear," Beth Janicek, board certified personal injury attorney

 

Free Consultation on your case.

Call Now Toll Free

1-877-795-3425

or Send Email

More at our Website

 

 

Search for more about this topic on SeniorJournal.com

Google Web SeniorJournal.com

Keep up with the latest news for senior citizens, baby boomers

 

Click to More Senior News on the Front Page

Copyright: SeniorJournal.com

    

 

Published by New Tech Media - www.NewTechMedia.com

Other New Tech Media sites include CaroleSutherland.com, BethJanicek.com, SASeniors.com, DrugDanger.com, etc.